UnitedHealth Group Files Definitive Proxy Statement

Ticker: UNH · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 731766

Unitedhealth Group Inc DEF 14A Filing Summary
FieldDetail
CompanyUnitedhealth Group Inc (UNH)
Form TypeDEF 14A
Filed DateApr 22, 2024
Risk Levellow
Pages14
Reading Time17 min
Key Dollar Amounts$6 billion, $371.6 billion, $324.2 billion, $22.4 billion, $32.4 billion
Sentimentneutral

Sentiment: neutral

Topics: UnitedHealth Group, Proxy Statement, DEF 14A, Healthcare, Optum

TL;DR

<b>UnitedHealth Group files its definitive proxy statement, outlining its mission and business operations.</b>

AI Summary

UNITEDHEALTH GROUP INC (UNH) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. UnitedHealth Group is a health care and well-being company with approximately 400,000 colleagues. The company operates through two distinct businesses: Optum and UnitedHealthcare. Optum combines clinical expertise, technology, and data to empower individuals, partners, and providers. UnitedHealthcare offers a full range of health benefits, simplifying the healthcare experience. The company aims to care for over 150 million individuals, promoting a value-based system of care.

Why It Matters

For investors and stakeholders tracking UNITEDHEALTH GROUP INC, this filing contains several important signals. This filing provides shareholders with essential information regarding the company's governance and strategic priorities ahead of shareholder meetings. The proxy statement details UnitedHealth Group's commitment to improving healthcare access, affordability, and outcomes through its diverse business segments.

Risk Assessment

Risk Level: low — UNITEDHEALTH GROUP INC shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational disclosures that would indicate a change in risk.

Analyst Insight

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand governance and potential strategic shifts.

Key Numbers

  • 400,000 — Colleagues (Approximate number of employees)
  • 150 million — Individuals Served (Number of individuals cared for by UnitedHealthcare)
  • 2024-06-03 — Report Period End Date (Conformed period of report)
  • 2024-04-22 — Filing Date (Date the filing was made)

Key Players & Entities

  • UNITEDHEALTH GROUP INC (company) — Filer name
  • 0000731766 (company) — Central Index Key
  • 411321939 (company) — IRS Number
  • DE (company) — State of Incorporation
  • 1231 (company) — Fiscal Year End
  • 001-10864 (company) — SEC File Number
  • 24861858 (company) — Film Number
  • MINNEAPOLIS (company) — Business Address City

FAQ

When did UNITEDHEALTH GROUP INC file this DEF 14A?

UNITEDHEALTH GROUP INC filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by UNITEDHEALTH GROUP INC (UNH).

Where can I read the original DEF 14A filing from UNITEDHEALTH GROUP INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by UNITEDHEALTH GROUP INC.

What are the key takeaways from UNITEDHEALTH GROUP INC's DEF 14A?

UNITEDHEALTH GROUP INC filed this DEF 14A on April 22, 2024. Key takeaways: UnitedHealth Group is a health care and well-being company with approximately 400,000 colleagues.. The company operates through two distinct businesses: Optum and UnitedHealthcare.. Optum combines clinical expertise, technology, and data to empower individuals, partners, and providers..

Is UNITEDHEALTH GROUP INC a risky investment based on this filing?

Based on this DEF 14A, UNITEDHEALTH GROUP INC presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational disclosures that would indicate a change in risk.

What should investors do after reading UNITEDHEALTH GROUP INC's DEF 14A?

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand governance and potential strategic shifts. The overall sentiment from this filing is neutral.

Key Dates

  • 2024-04-22: Filing Date — Definitive Proxy Statement filed
  • 2024-06-03: Report Period End — Conformed period of report for the proxy statement

Glossary

DEF 14A
Definitive Proxy Statement (This is the form type filed by UnitedHealth Group, indicating it's a final proxy statement for shareholders.)
Optum
A business segment of UnitedHealth Group that combines clinical expertise, technology, and data. (Key to the company's strategy for empowering people, partners, and providers.)
UnitedHealthcare
A business segment of UnitedHealth Group offering health benefits. (Responsible for providing affordable coverage and simplifying the healthcare experience for millions.)
Value-based care
A healthcare delivery model focused on quality of care over quantity. (One of UnitedHealth Group's five strategic growth priorities.)

Filing Stats: 4,346 words · 17 min read · ~14 pages · Grade level 14.9 · Accepted 2024-04-22 16:59:50

Key Financial Figures

  • $6 billion — . As of April 20, we advanced more than $6 billion in an ongoing effort to support care pr
  • $371.6 billion — Financial Revenues increased 15% to $371.6 billion in 2023 from $324.2 billion in 2022;
  • $324.2 billion — ased 15% to $371.6 billion in 2023 from $324.2 billion in 2022; Net earnings increased 11% y
  • $22.4 billion — arnings increased 11% year-over-year to $22.4 billion; operating earnings increased 14% year-
  • $32.4 billion — arnings increased 14% year-over-year to $32.4 billion; and cash flow from operations increase
  • $29.1 billion — rations increased 11% year-over-year to $29.1 billion in 2023; Fully diluted earnings per s
  • $23.86 — ted earnings per share increased 13% to $23.86 per share from $21.18 in 2022. Adjusted
  • $21.18 — increased 13% to $23.86 per share from $21.18 in 2022. Adjusted earnings per share 1
  • $25.12 — earnings per share 1 increased 13% to $25.12 per share from $22.19 per share in 2022
  • $22.19 — increased 13% to $25.12 per share from $22.19 per share in 2022; Return on equity a
  • $7.52 — annual cash dividend rate increased to $7.52 per share, representing a 14% increase
  • $6.60 — e over the annual cash dividend rate of $6.60 per share since the second quarter of 2

Filing Documents

Executive Compensation

Executive Compensation 66 Audit 67 Audit and Finance Committee Report 67 Disclosure of Fees Paid to Independent Registered Public Accounting Firm 69 Audit and Finance Committee's Consideration of Independence of Independent Registered Public Accounting Firm 69 Audit and Non-Audit Services Approval Policy 69 PROPOSAL 3: Ratification of Independent Registered Public Accounting Firm 70 Annual Meeting 71 PROPOSAL 4: Shareholder Proposal Requiring a Political Contributions Congruency Report 71 Questions and Answers About the Annual Meeting and Voting 74 Householding Notice 81 Other Matters at Meeting 81 Other Information 82

Security Ownership of Certain Beneficial Owners

Security Ownership of Certain Beneficial Owners and Management 82 Certain Relationships and Transactions 84 Appendix A—Reconciliation of Non-GAAP Financial Measure 86 TABLE OF CONTENTS Proxy Summary Business Results UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. We have approximately 400,000 colleagues in two distinct and complementary businesses working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences. Optum combines clinical expertise, technology and data to empower people, partners and providers with the information, tools and assistance they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Financial Revenues increased 15% to $371.6 billion in 2023 from $324.2 billion in 2022; Net earnings increased 11% year-over-year to $22.4 billion; operating earnings increased 14% year-over-year to $32.4 billion; and cash flow from operations increased 11% year-over-year to $29.1 billion in 2023; Fully diluted earnings per share increased 13% to $23.86 per share from $21.18 in 2022. Adjusted earnings per share 1 increased 13% to $25.12 per share from $22.19 per share in 2022; Return on equity at 27.0% in 2023 compared with 27.2% in 2022; The annual cash dividend rate increased to $7.52 per share, representing a 14% increase over the annual cash dividend rate of $6.60 per share since the second quarter of 2022; and Total shareholder return was 123% for the five-year period ended 2023. Awards and Recognition We were the top ranked company in the insurance and managed care sector on Fortune's 2024 "World's Most Admired Companies" list. This is the 14th consecutive year we have ranked No. 1 overall in

Executive Compensation

Executive Compensation Our executive compensation program uses a mix of base salary, annual cash incentives, stock compensation awards and broad-based benefits to attract and retain highly qualified executives and maintain a strong alignment between executive pay and Company performance. Information regarding our named executive officers' compensation in 2023 is described in the "Executive Compensation" section. Shareholders expressed strong support for our executive compensation program at our 2023 Annual Meeting of Shareholders, with 96% of the votes cast in favor of our Say-on-Pay proposal. Voting Matters and Vote Recommendations Items of Business Board's Recommendation Details 1 Election of Ten Directors FOR Page 4 2 Advisory Approval of Executive Compensation FOR Page 66 3 Ratification of Independent Registered Public Accounting Firm FOR Page 70 4 Shareholder Proposal Requiring a Political Contributions Congruency Report AGAINST Page 71 2024 Proxy Statement |Proxy Summary 3 TABLE OF CONTENTS 1 Board of Directors 2 Corporate Governance 3 Executive Compensation 4 Audit 5 Annual Meeting 6 Other Information Board of Directors PROPOSAL 1: Election of Directors Our Board of Directors has nominated ten directors for election at the 2024 Annual Meeting to hold office until the next annual meeting and the election of their successors. All nominees are currently directors and have agreed to be named in this proxy statement and to serve if elected. In accordance with our Principles of Governance, each nominee has also tendered an irrevocable offer to resign as a director, which will become effective if the director fails to receive a majority vote for election at the Annual Meeting and our Board accepts the director's offer to resign. Please see the "Corporate Governance" section of this proxy statement for additional details on this policy. All nominees are expected to attend the 2024 A

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.